Defining minimal residual disease by flow cytometry in acute myeloid leukemia: the HARMONIZE initiativeVeit Bücklein, Malte von Bonin, S. Krause et al.|Unknown|2017Cited by 0
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Stefanie Goellner et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0